Literature DB >> 20585130

In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.

Kozue Kishii1, Naoko Chiba, Miyuki Morozumi, Akiko Ono, Takashi Ida, Kimiko Ubukata.   

Abstract

In vitro activity of tebipenem, a new oral carbapenem antibiotic, against clinical Haemophilus influenzae isolates was compared with those of 8 reference agents. Isolates were classified into 6 resistance classes after PCR identification of beta-lactamase genes and ftsI gene mutations. For all isolates, the minimal concentration at which 90% of isolates were inhibited was lower for tebipenem than for the reference oral antibiotics, except for cefditoren. Tebipenem also showed excellent bactericidal activity against beta-lactamase-nonproducing, ampicillin-resistant isolates.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20585130      PMCID： PMC2934951          DOI： 10.1128/AAC.00054-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.

Authors:  K Ubukata; Y Shibasaki; K Yamamoto; N Chiba; K Hasegawa; Y Takeuchi; K Sunakawa; M Inoue; M Konno
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases.

Authors:  I Massova; S Mobashery
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

3.  In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae.

Authors:  Reiko Kobayashi; Mami Konomi; Keiko Hasegawa; Miyuki Morozumi; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Molecular evolution of beta-lactam-resistant Haemophilus influenzae: 9-year surveillance of penicillin-binding protein 3 mutations in isolates from Japan.

Authors:  Yumiko Sanbongi; Takahisa Suzuki; Yumi Osaki; Nami Senju; Takashi Ida; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Lysis of Escherichia coli by beta-lactams which bind penicillin-binding proteins 1a and 1b: inhibition by heat shock proteins.

Authors:  J K Powell; K D Young
Journal:  J Bacteriol       Date:  1991-07       Impact factor: 3.490

6.  In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.

Authors:  M Hikida; K Itahashi; A Igarashi; T Shiba; M Kitamura
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

7.  Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States.

Authors:  Keiko Hasegawa; Kentarou Yamamoto; Naoko Chiba; Reiko Kobayashi; Kensuke Nagai; Michael R Jacobs; Peter C Appelbaum; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

8.  In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.

Authors:  S Miyazaki; T Hosoyama; N Furuya; Y Ishii; T Matsumoto; A Ohno; K Tateda; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Rapidly increasing prevalence of beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis.

Authors:  Keiko Hasegawa; Naoko Chiba; Reiko Kobayashi; Somay Y Murayama; Satoshi Iwata; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.